Thomas Hogan Sells 103,188 Shares of Cellebrite DI (NASDAQ:CLBT) Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CEO Thomas Hogan sold 103,188 shares of Cellebrite DI stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $15.76, for a total transaction of $1,626,242.88. Following the completion of the transaction, the chief executive officer directly owned 590,777 shares of the company’s stock, valued at $9,310,645.52. This trade represents a 14.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Cellebrite DI Stock Down 0.4%

Shares of NASDAQ:CLBT opened at $16.51 on Thursday. The firm has a 50-day simple moving average of $13.64 and a 200 day simple moving average of $14.55. The company has a market cap of $4.12 billion, a PE ratio of 58.97, a P/E/G ratio of 2.05 and a beta of 1.17. Cellebrite DI Ltd. has a fifty-two week low of $11.02 and a fifty-two week high of $19.98.

Hedge Funds Weigh In On Cellebrite DI

Hedge funds and other institutional investors have recently modified their holdings of the stock. Elevation Wealth Partners LLC purchased a new stake in Cellebrite DI during the second quarter valued at about $44,000. Moody National Bank Trust Division increased its position in shares of Cellebrite DI by 7.6% in the second quarter. Moody National Bank Trust Division now owns 60,691 shares of the company’s stock worth $886,000 after acquiring an additional 4,284 shares in the last quarter. Pacer Advisors Inc. raised its holdings in shares of Cellebrite DI by 91.1% during the first quarter. Pacer Advisors Inc. now owns 7,607 shares of the company’s stock valued at $105,000 after acquiring an additional 3,626 shares during the period. Alpine Woods Capital Investors LLC acquired a new stake in shares of Cellebrite DI during the first quarter valued at approximately $223,000. Finally, Evolutionary Tree Capital Management LLC lifted its position in shares of Cellebrite DI by 22.6% in the 1st quarter. Evolutionary Tree Capital Management LLC now owns 183,473 shares of the company’s stock valued at $2,528,000 after acquiring an additional 33,829 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Wall Street Analysts Forecast Growth

CLBT has been the subject of several recent research reports. DA Davidson started coverage on shares of Cellebrite DI in a research report on Wednesday, May 27th. They set a “buy” rating and a $20.00 price target for the company. Wall Street Zen raised Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Finally, Needham & Company LLC decreased their price objective on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, May 15th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $21.40.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.